MX2020007692A - Composiciones oftalmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificacion. - Google Patents

Composiciones oftalmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificacion.

Info

Publication number
MX2020007692A
MX2020007692A MX2020007692A MX2020007692A MX2020007692A MX 2020007692 A MX2020007692 A MX 2020007692A MX 2020007692 A MX2020007692 A MX 2020007692A MX 2020007692 A MX2020007692 A MX 2020007692A MX 2020007692 A MX2020007692 A MX 2020007692A
Authority
MX
Mexico
Prior art keywords
bilastine
cyclodextrin
gelling agent
beta
ophthalmic compositions
Prior art date
Application number
MX2020007692A
Other languages
English (en)
Inventor
Herrero Gonzalo Hernández
Gorostiza Ana Gonzalo
Arce Arturo Zazpe
Poladura Pablo Morán
García Tania González
Hernando Nieves Fernández
Cerdeiras Paloma Tato
Espinar Francisco Javier Otero
Ferreiro Anxo Fernández
Tomé Victoria Díaz
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of MX2020007692A publication Critical patent/MX2020007692A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una composición farmacéutica oftálmica acuosa que comprende: a) al menos el 0,4% p/5 v de bilastina, de fórmula (ver formula) o una sal o solvato farmacéuticamente aceptable de la misma, en la que la bilastina, sal o solvato de la misma se disuelve completamente en la composición farmacéutica; b) al menos una ?-ciclodextrina; y c) al menos un agente de gelificación soluble en agua farmacéuticamente aceptable; y en la que el pH está comprendido entre 4 y 9, y a su uso en el tratamiento y/o la prevención de estados mediados por receptor de histamina H1, tales como trastornos o enfermedades alérgicos. La invención se refiere al tratamiento y/o prevención de conjuntivitis alérgica.
MX2020007692A 2018-01-18 2019-01-09 Composiciones oftalmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificacion. MX2020007692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382021 2018-01-18
PCT/EP2019/050433 WO2019141563A1 (en) 2018-01-18 2019-01-09 Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent

Publications (1)

Publication Number Publication Date
MX2020007692A true MX2020007692A (es) 2020-09-14

Family

ID=61017875

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007692A MX2020007692A (es) 2018-01-18 2019-01-09 Composiciones oftalmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificacion.

Country Status (27)

Country Link
US (1) US20210128544A1 (es)
EP (2) EP3740191B1 (es)
JP (1) JP7309729B2 (es)
KR (1) KR102695627B1 (es)
CN (1) CN111727035B (es)
AR (1) AR114216A1 (es)
AU (1) AU2019209214B2 (es)
BR (1) BR112020014265A2 (es)
CA (1) CA3088740A1 (es)
CL (1) CL2020001895A1 (es)
CO (1) CO2020009992A2 (es)
CY (1) CY1124270T1 (es)
DK (1) DK3740191T3 (es)
EA (1) EA202091725A1 (es)
ES (1) ES2878107T3 (es)
HR (1) HRP20211037T1 (es)
HU (1) HUE054594T2 (es)
LT (1) LT3740191T (es)
MA (1) MA51612B1 (es)
MX (1) MX2020007692A (es)
PL (1) PL3740191T3 (es)
PT (1) PT3740191T (es)
SA (1) SA520412443B1 (es)
SI (1) SI3740191T1 (es)
TW (1) TWI833727B (es)
UY (1) UY38055A (es)
WO (1) WO2019141563A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023156559A1 (en) 2022-02-17 2023-08-24 Faes Farma, S.A. Bilastine composition for once-daily parenteral administration
CN115970066B (zh) * 2022-12-29 2024-09-27 成都爱睿康乐医疗器械有限公司 基于主客体相互作用的载药纳米凝胶生物润滑剂及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
JP3527256B2 (ja) 1992-12-09 2004-05-17 ロート製薬株式会社 抗アレルギー点眼剤
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
SK288052B6 (sk) 2002-04-19 2013-03-01 Faes Farma, S.A. Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US7247623B2 (en) * 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
UA94938C2 (ru) * 2006-03-31 2011-06-25 ВИСТЕКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты)
EP2004196B1 (en) * 2006-03-31 2016-06-29 Vistakon Pharmaceuticals, LLC Ocular allergy treatments
WO2009003199A1 (en) 2007-06-28 2008-12-31 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
WO2010107525A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN103110575B (zh) * 2013-03-07 2014-11-05 宁夏康亚药业有限公司 一种美洛昔康滴眼液及其制备方法和应用
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
CN103784462A (zh) * 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents

Also Published As

Publication number Publication date
JP7309729B2 (ja) 2023-07-18
MA51612A (fr) 2020-11-25
SI3740191T1 (sl) 2021-09-30
EP3915539A1 (en) 2021-12-01
KR102695627B1 (ko) 2024-08-16
CY1124270T1 (el) 2022-07-22
EP3740191B1 (en) 2021-04-28
HUE054594T2 (hu) 2021-09-28
CN111727035B (zh) 2024-05-28
WO2019141563A1 (en) 2019-07-25
HRP20211037T1 (hr) 2021-10-01
TWI833727B (zh) 2024-03-01
KR20200111727A (ko) 2020-09-29
PL3740191T3 (pl) 2021-11-29
AR114216A1 (es) 2020-08-05
AU2019209214A1 (en) 2020-08-13
CO2020009992A2 (es) 2021-01-18
CL2020001895A1 (es) 2020-12-04
BR112020014265A2 (pt) 2020-12-08
EA202091725A1 (ru) 2020-10-12
US20210128544A1 (en) 2021-05-06
ES2878107T3 (es) 2021-11-18
EP3740191A1 (en) 2020-11-25
MA51612B1 (fr) 2021-06-30
CN111727035A (zh) 2020-09-29
DK3740191T3 (da) 2021-06-07
LT3740191T (lt) 2021-08-10
TW201932110A (zh) 2019-08-16
UY38055A (es) 2019-08-30
AU2019209214B2 (en) 2023-11-23
JP2021511317A (ja) 2021-05-06
CA3088740A1 (en) 2019-07-25
SA520412443B1 (ar) 2022-09-01
PT3740191T (pt) 2021-07-09

Similar Documents

Publication Publication Date Title
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011196A (es) Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
MX2022006736A (es) Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
MX2021013135A (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
SA520412443B1 (ar) تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
MX2009007040A (es) Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.
MX2023007036A (es) Formulaciones de liberacion prolongada para aplicaciones intra-articulares.
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2023011546A (es) Composiciones nasales que comprenden alcaftadina.
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
NO20074371L (no) Anthelmintiske imidazol-tiazolderivater
AU2017261303A1 (en) Ophthalmic compositions
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
EA202090965A1 (ru) Водные композиции биластина
PH12020551418A1 (en) Methods of use and pharmaceutical compositions of a selective syk inhibitor
MX2023015246A (es) Compuestos pirimidinicos para usar como inhibidores de map4k1.